ARQT — Arcutis Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- $1.73bn
- $1.61bn
- $196.54m
- 27
- 10
- 90
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11 | ||
| Price to Tang. Book | 11.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.82 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.93% | ||
| Return on Equity | -113.76% | ||
| Operating Margin | -65.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 3.69 | 59.61 | 196.54 | 304.42 | 429.97 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Directors
- Patrick Heron CHM (51)
- Todd Watanabe PRE (53)
- David Osborne CFD (60)
- Scott Burrows CFO (44)
- Matthew Moore SVP (48)
- Patricia Turney SVP (54)
- Rajvir Madan CIO
- Courtney Barton CCO
- Jay Ramsinghani VOP
- Kimberly Lathroum VPR
- Heather Armstrong VPR
- David Berk VPR (41)
- Bruce Binkowitz VPR
- Bethany Dudek VPR
- Meg Elias VPR (54)
- Ayisha Jeter VPR
- Charlotte Merritt VPR (57)
- Frank Pompilio VPR (56)
- Masaru Matsuda GCN
- Patrick Burnett OTH (49)
- Kenneth Lock OTH (47)
- Terrie Curran DRC (52)
- Halley Gilbert DRC (51)
- Keith Leonard DRC (59)
- Sue-Jean Lin DRC
- Howard Welgus DRC (69)
- Bhaskar Chaudhuri IND (67)
- Joseph Turner IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 1st, 2016
- Public Since
- January 31st, 2020
- No. of Shareholders
- 61
- No. of Employees
- 342
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 118,638,235
- Address
- 3027 Townsgate Road, Suite 300, WESTLAKE VILLAGE, 91361
- Web
- https://arcutis.com/
- Phone
- +1 8054185006
- Auditors
- Ernst & Young LLP
Upcoming Events for ARQT
Q1 2025 Arcutis Biotherapeutics Inc Earnings Call
Arcutis Biotherapeutics Inc Annual Shareholders Meeting
Q2 2025 Arcutis Biotherapeutics Inc Earnings Release
Similar to ARQT
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Arcutis Biotherapeutics share price?
As of Today at 19:20 UTC, shares in Arcutis Biotherapeutics are trading at $14.61. This share price information is delayed by 15 minutes.
How has the Arcutis Biotherapeutics share price performed this year?
Shares in Arcutis Biotherapeutics last closed at $14.61 and the price had moved by +70.08% over the past 365 days. In terms of relative price strength the Arcutis Biotherapeutics share price has outperformed the S&P500 Index by +56.99% over the past year.
What are the analyst and broker recommendations for Arcutis Biotherapeutics?
The overall consensus recommendation for Arcutis Biotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Arcutis Biotherapeutics dividend yield?
Arcutis Biotherapeutics does not currently pay a dividend.
Does Arcutis Biotherapeutics pay a dividend?
Arcutis Biotherapeutics does not currently pay a dividend.
When does Arcutis Biotherapeutics next pay dividends?
Arcutis Biotherapeutics does not currently pay a dividend.
How do I buy Arcutis Biotherapeutics shares?
To buy shares in Arcutis Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arcutis Biotherapeutics?
As of the previous close price of $14.61, shares in Arcutis Biotherapeutics had a market capitalisation of $1.73bn.
Where are Arcutis Biotherapeutics shares listed?
Here are the trading details for Arcutis Biotherapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ARQT
What kind of share is Arcutis Biotherapeutics?
Based on an overall assessment of its quality, value and momentum Arcutis Biotherapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arcutis Biotherapeutics share price forecast for 2025?
The analyst consensus target price for shares in Arcutis Biotherapeutics is $21.00. That is 43.74% above the last closing price of $14.61.
Analysts covering Arcutis Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.59 for the next financial year.
Find out moreWhat is the trend in the Arcutis Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcutis Biotherapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +75.99%.
As of the last closing price of $14.61, shares in Arcutis Biotherapeutics were trading +23.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arcutis Biotherapeutics PE Ratio?
The Arcutis Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arcutis Biotherapeutics?
Arcutis Biotherapeutics' management team is headed by:
- Patrick Heron - CHM
- Todd Watanabe - PRE
- David Osborne - CFD
- Scott Burrows - CFO
- Matthew Moore - SVP
- Patricia Turney - SVP
- Rajvir Madan - CIO
- Courtney Barton - CCO
- Jay Ramsinghani - VOP
- Kimberly Lathroum - VPR
- Heather Armstrong - VPR
- David Berk - VPR
- Bruce Binkowitz - VPR
- Bethany Dudek - VPR
- Meg Elias - VPR
- Ayisha Jeter - VPR
- Charlotte Merritt - VPR
- Frank Pompilio - VPR
- Masaru Matsuda - GCN
- Patrick Burnett - OTH
- Kenneth Lock - OTH
- Terrie Curran - DRC
- Halley Gilbert - DRC
- Keith Leonard - DRC
- Sue-Jean Lin - DRC
- Howard Welgus - DRC
- Bhaskar Chaudhuri - IND
- Joseph Turner - IND